Laboratory Corporation of America
Q1 2022 Earnings Call
Apr 28, 2022, 9:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day, and thank you for standing by. Welcome to the Labcorp's first quarter 2022 earnings conference call. Please be advised that today's conference is being recorded. I would now hand the conference over to your speaker today, Chas Cook, vice president, investor relations.
Please go ahead.
Chas Cook -- Vice President, Investor Relations
Thank you, operator. Good morning, and welcome to Labcorp's first quarter 2022 conference call. As detailed in today's press release, there will be a replay of this conference call available via telephone and Internet. With me today are Adam Schechter, chairman and chief executive officer; and Glenn Eisenberg, executive vice president and chief financial officer.
This morning, in the Investor Relations section of our website at www.labcorp.com, we posted both our press release and an Investor Relations presentation with additional information on our businesses and operations, which include a reconciliation of the non-GAAP financial measures to the GAAP financial measures discussed during today's call. Additionally, we are making forward-looking statements. These forward-looking statements include, but are not limited to, statements with respect to the estimated 2022 guidance and the related assumptions, the impact of various factors on the company's businesses, operating and financial results, cash flows and/or financial condition, including the COVID-19 pandemic and the general economic and market conditions, our response to the COVID-19 pandemic, future business strategies, expected savings and synergies and opportunities for future growth. Each of the forward-looking statements is subject to the change based upon various factors, many of which are beyond our control.
More information is included in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and in the company's filings with the SEC. We have no obligation to provide any updates to these forward-looking statements even if our expectations change. Now I'll turn the call over to Adam Schechter.
Adam Schechter -- Chairman and Chief Executive Officer
Thank you, Chas, and good morning, everyone. Thanks for joining us today. In the first quarter, we continued to advance our strategy through science, innovation, and technology. We delivered a solid first quarter despite omicron, which had a significant impact across both businesses in January and continue to impact drug development outside the U.S.